Technical Analysis for KRTX - Karuna Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 53.27% | |
180 Bullish Setup | Bullish Swing Setup | 53.27% | |
NR7 | Range Contraction | 53.27% | |
Slingshot Bullish | Bullish Swing Setup | 56.04% | |
Overbought Stochastic | Strength | 56.04% | |
NR7 | Range Contraction | 50.58% | |
Doji - Bearish? | Reversal | 50.58% | |
Gapped Up | Strength | 50.58% | |
Overbought Stochastic | Strength | 50.58% | |
Stochastic Sell Signal | Bearish | 52.70% |
Get a Trading Sidekick!
- Earnings date: 05/02/2024
Karuna Therapeutics, Inc. Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Alzheimer's Disease Schizophrenia Central Nervous System Disorders Nervous System Disorders Psychosis Treatment Of Central Nervous System Disorders Puretech Health
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 329.99 |
52 Week Low | 158.375 |
Average Volume | 765,183 |
200-Day Moving Average | 228.31 |
50-Day Moving Average | 317.38 |
20-Day Moving Average | 319.40 |
10-Day Moving Average | 321.59 |
Average True Range | 3.32 |
RSI (14) | 75.43 |
ADX | 33.43 |
+DI | 31.89 |
-DI | 21.73 |
Chandelier Exit (Long, 3 ATRs) | 320.04 |
Chandelier Exit (Short, 3 ATRs) | 306.01 |
Upper Bollinger Bands | 327.48 |
Lower Bollinger Band | 311.31 |
Percent B (%b) | 1.15 |
BandWidth | 5.06 |
MACD Line | 3.83 |
MACD Signal Line | 3.22 |
MACD Histogram | 0.6037 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 330.19 | ||||
Resistance 3 (R3) | 330.20 | 330.10 | 330.13 | ||
Resistance 2 (R2) | 330.10 | 330.00 | 330.09 | 330.11 | |
Resistance 1 (R1) | 329.96 | 329.95 | 330.03 | 329.95 | 330.09 |
Pivot Point | 329.86 | 329.86 | 329.89 | 329.85 | 329.86 |
Support 1 (S1) | 329.72 | 329.76 | 329.79 | 329.71 | 329.57 |
Support 2 (S2) | 329.62 | 329.71 | 329.61 | 329.55 | |
Support 3 (S3) | 329.48 | 329.62 | 329.53 | ||
Support 4 (S4) | 329.47 |